GeoVax Labs Faces Delisting Concerns

TL;DR

GeoVax might get delisted, stock trading could be in trouble.

AI Summary

GeoVax Labs, Inc. filed an 8-K on June 21, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule. The filing indicates potential issues with the company's continued listing on a stock exchange, which could impact its trading status.

Why It Matters

This filing signals potential delisting, which could significantly impact the liquidity and trading of GeoVax Labs' stock.

Risk Assessment

Risk Level: high — A notice of delisting directly threatens the company's ability to remain publicly traded, posing a significant risk to investors.

Key Players & Entities

• GeoVax Labs, Inc. (company) — Registrant
• June 20, 2024 (date) — Earliest event reported
• June 21, 2024 (date) — Filing date

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock , par value $0.001 per share GOVX The Nasdaq Capital Ma
• $1.3 million — securities purchase agreement to issue $1.3 million in common stock and warrants (the "Offe
• $1.68 — of common stock ("Units") at a price of $1.68 per Unit. The Nasdaq Official Closing P
• $1.65 — l Closing Price ("NOCP") for GeoVax was $1.65 as of May 20, 2024, and the five-day av
• $1.70 — rage NOCP for the period then ended was $1.70. The Units were priced at $1.68; howeve
• $0 — ; however, after attributing a value of $0.25, which represents 200% warrant cover
• $1.90 — age, the Minimum Price would need to be $1.90 per Unit. When the Company entered into

Filing Documents

• govx20240614_8k.htm (8-K) — 34KB
• ex_688702.htm (EX-4.1) — 14KB
• 0001437749-24-020958.txt ( ) — 199KB
• govx-20240620.xsd (EX-101.SCH) — 4KB
• govx-20240620_def.xml (EX-101.DEF) — 13KB
• govx-20240620_lab.xml (EX-101.LAB) — 17KB
• govx-20240620_pre.xml (EX-101.PRE) — 13KB
• govx20240614_8k_htm.xml (XML) — 5KB

01

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On June 20, 2024, the Company received a letter (the "Letter") from the Listing Qualifications Department (the "Staff") of the Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it failed to comply with Nasdaq's shareholder approval requirements set forth in Nasdaq Listing Rule 5635(d) (the "Rule"), which requires prior shareholder approval for transactions, other than public offerings, involving the issuance of 20% or more of the pre-transaction shares outstanding at less than the Minimum Price (as defined in the Rule), in connection with the Company's private placement that closed on May 21, 2024. The Letter also notified the Company of the Staff's determination that the Company had remediated the deficiency and regained compliance with the Rule, and the matter is now closed, as further described herein. Nasdaq's Letter has no effect on the listing of the Company's Common Stock (as defined below) on The Nasdaq Capital Market. On May 16, 2024, the Company entered into a securities purchase agreement to issue $1.3 million in common stock and warrants (the "Offering"). The Offering included 802,844 shares of common stock and warrants (the "Common Warrants") to purchase up to 1,605,688 shares of common stock ("Units") at a price of $1.68 per Unit. The Nasdaq Official Closing Price ("NOCP") for GeoVax was $1.65 as of May 20, 2024, and the five-day average NOCP for the period then ended was $1.70. The Units were priced at $1.68; however, after attributing a value of $0.25, which represents 200% warrant coverage, the Minimum Price would need to be $1.90 per Unit. When the Company entered into the Offering, the Company had 2,308,309 shares of common stock outstanding. As such, the Offering represented a greater than 20% issuance of the common stock outstanding and was priced below the Minimum Price. In light of the foregoing, the Company was requ

03

Item 3.03 Material Modification to Rights of Security Holders. On June 14, 2024, the Company entered a side letter with an institutional investor (the "Investor") dated June 14, 2024 (the "Side Letter") to amend the Common Stock Purchase Warrant dated as of May 21, 2024 (the "Warrant"), issued by the Company to the Investor, to amend the definition of "Initial Exercise Date" to be "the date on which the approval, as required by the applicable rules and regulations of the Trading Market, from the Company's stockholders with respect to the issuance of this Warrant is obtained." The foregoing description of the Side Letter is qualified in its entirety by reference to the Side Letter, which is attached as Exhibit 4.1 attached hereto and incorporated by reference herein.

Financial Statements and Exhibits

Financial Statements and Exhibits (d) Exhibits. Exhibit No. Description 4.1 Side Letter dated June 14, 2024, by and between the Company and the Investor 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 21, 2024 GEOVAX LABS, INC. By: /s/ Mark W. Reynolds Mark W. Reynolds Chief Financial Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR